Merida Biosciences is developing antibody-like drugs designed to selectively eliminate disease-driving autoantibodies while sparing healthy components of the immune system. Graves disease, which stems from the immune system’s attack on the thyroid gland, is the startup’s lead disease target.
The post Immunology Startup Merida Bio Unveils $121M and a Lead Program for Graves’ Disease appeared first on MedCity News.
